

Dr Chris Jones

Publications

Since 2010

N. Ravenscroft, J.X. Wheeler, **C. Jones** "Bioanalysis of meningococcal vaccines", *Bioanalysis*, 2010, **2**, 343-361.

L.F. Hallack, D.S. Passos, K.A. Mattos, O.A. Agrellos, **C. Jones**, L. Mendonça-Previato, J.O. Previato, and A.R. Todeschini, "Structural elucidation of the repeat unit in highly branched acidic exopolysaccharides produced by nitrogen fixing *Burkholderia*", *Glycobiology*, 2010, **20**, 338-347.

Y. Aubin, **C. Jones** and D.I. Freedberg: "NMR Spectroscopy can obtain Information on Higher Order Structure of Biopharmaceutical Products: Simple methods can characterize poly-saccharide vaccines and recombinant cytokines at high resolution", *Biopharm. Int.* 2010, August Supplement, 28-34.

J. Ravi, D. Schiffmann, R. Tantra, S. Cox, J. Eady, **C. Jones**, J. Vrettos, J. DeSa Lorenz, Y. Shigeri, H. Masago, S. Linghui, K. Emslie, R. Willows, P. Charlet, Y. Dupont, C.W. Meuse, M.J.A. Bailey, and A.E. Knight, "International comparability in spectroscopic measurements of protein structure by circular dichroism: CCQM-P59." *Metrologia*, 2010. **47**(1A):08022. See <http://iopscience.iop.org/0026-1394/47/1A/08022>.

J. Ravi, P. Rakowska, T. Garfagnini, B. Baron, P. Charlet, **C. Jones**, J. DeSa Lorenz, D. Plusquellic, F. Wien, L. Wu, C.W. Meuse and A.E. Knight, "International comparability in spectroscopic measurements of protein structure by circular dichroism: CCQM-P59.1", *Metrologia*, 2010, **47**, 631-641.

J. Robinson and **C. Jones**, "Quality Control and Analytical Techniques for Biopharmaceuticals", *Bioanalysis*, 2011, **3**(1), 81-95.

R. Chen, I. Vendrell, J.E. Preston, D. Cash, **C. Jones**, S.A. Williams and J.X. Wheeler, "Proteomic analysis of rat plasma following transient focal cerebral ischaemia", *Biomark. Med*, 2011, **5**(6), 837-846.

O. Xie, B. Bolgiano, F. Gao, K. Lockyer, C. Swann, **C. Jones**, I. Delrieu, B.-M. Njanpop-Lafourcade, T. Agbeko Tamekloe, A.J. Pollard, and G. Norheim, "Characterisation of size and structure of serogroup X *N. meningitidis* polysaccharide, and development of an assay for quantification of human antibodies", *Vaccine*, 2012, **30**(40), 5812-23.

C. Jones, “Stability of polysaccharides in vaccines”, RSC Special Report “*Stability of complex carbohydrate structures*” (S. Harding Ed.), 2013, RSC, Cambridge, pp. 56-67.

M.B. Oliver, **C. Jones**, T.R. Larson, J.J. Calix, E.R. Zartler, J. Yother and M.H. Nahm, “*Streptococcus pneumoniae* serotype 11D has a bi-specific glycosyltransferase and expresses two different capsular polysaccharides”, *J. Biol. Chem.*, 2013, **288**, 21945-21954.

L. Mendonça Previato, L. Penha, T. Cortes Galvez, **C. Jones** and J.O. Previato, “Addition of β -O-GlcNAc to threonine residues define the post-translational modification of mucin-like molecules in *Trypanosoma cruzi*”, *Glycoconjugate J.*, 2013, 30, 659-666.

S. Kothari, N. Kothari, Jeong-Ah Kim, E. Lee, Y.K. Yoon, So Jung An, **C. Jones**, Woo Seok Choe, and R. Carbis “A novel method for purification of Vi capsular polysaccharide produced by *Salmonella enterica* subspecies *enterica* Serovar Typhi”, *Vaccine*, 2013, 31, 4714-4719.

S. Kothari, J.-A. Kim, N. Kothari, **C. Jones**, W. S. Choe and R. Carbis, “Purification of O-specific polysaccharide from lipopolysaccharide produced by *Salmonella enterica* serovar Paratyphi A”, *Vaccine*, 2014, 32(21), 2457-2462.

Recent regulatory documents: WHO

“Guidelines on the quality, safety and efficacy of typhoid conjugate vaccines”,
http://www.who.int/biologicals/areas/vaccines/TYPHOID_BS2215_doc_v1.14_WEB_VERSION.pdf.

“Recommendations to assure the quality, safety and efficacy of Group A meningococcal conjugate vaccines”.

<http://www.who.int/biologicals/publications/trs/areas/vaccines/meningococcal/MenA%20Final%20BS204102.Nov.06.pdf?ua=1>

Regulatory documents: USP

“<1238> *Vaccines for Human Use—Bacterial Vaccines*”, *Pharmacopeial Forum*, 2011, 37(4), Member of Expert Panel that drafted the chapter.

“<1234> *Vaccines for human use – Polysaccharide and Glycoconjugate vaccines*”, *Pharmacopeial Forum*, 2013, 39(4). Chair of Expert Panel that drafted this chapter.

“<1239> *Vaccines for Human Use – Viral Vaccines, General Considerations*”, *Pharmacopeial Forum*, 2014, 40 (5), Member of Expert Panel that drafted this chapter.

“<***> *Identity Testing of Bacterial Polysaccharides used in Vaccine Manufacture by NMR Spectroscopy*”, *Pharmacopeial Forum*, in preparation. Chair of Expert Panel that drafted this chapter.

"<1084> *Glycoprotein and Glycan Analysis—General Considerations*", *Pharmacoepial Forum*, 2010, 36(2). Chair of Expert Panel that drafted this chapter.

"<212> *Glycoprotein and Glycan Analysis—Oligosaccharide analysis*", *Pharmacoepial Forum*, 2014, 40(3). Chair of Expert Panel that drafted this chapter.

"<210> *Glycoprotein and Glycan Analysis—Monosaccharide analysis*", *Pharmacoepial Forum*, in preparation. Chair of Expert Panel drafting this chapter.

"<1055> *Biotechnology-derived articles – Peptide mapping*", *Pharmacoepial Forum*, 2014, 40(3). Member of Working Group that re-drafted this chapter.
